Evaluation of separate role of intestine and liver in first pass metabolism of budesonide in rat

Abstract

1. Budesonide, a potent topical corticosteroid, reported to have low oral bioavailability in mice, rat, dog and human due to rapid first pass metabolism. However, there is insufficient information available in literature regarding the role of intestine and or liver responsible for the first pass metabolism of budesonide.

2. Current study in rats investigates the role of intestine and liver in first pass metabolism of budesonide using two in vivo models. Additionally, budesonide was also evaluated in in vitro assays such as thermodynamic solubility, permeability in Caco-2 cells and stability in simulated gastric (SGF), intestinal fluids (SIF) to understand the underlaying cause for low oral bioavailability.

3. Budesonide showed low oral, intra-duodenal and high intra-portal bioavailability in rat. In a dual vein cannulated rat model, intestinal and hepatic extraction ratios calculated based upon intestinal availability (Fa·Fg) and hepatic availability (Fh), suggests hepatic extraction of budesonide is minimal compared to intestinal.

4. In vitro results suggest, solubility and permeability may not be a barrier for the observed low oral bioavailability in rats.

5. Correlating the in vitro and in vivo data together, it can be concluded that, intestine might be playing major role in first pass metabolism of budesonide.

Keywords:

• Budesonide
• first-pass metabolism
• low bioavailability
• portal vein cannulated rats

Acknowledgments

We are grateful to Senior Leadership Team of Advinus for their valuable suggestions. Advinus publication number ADV-A-048.

Declaration of interest

The authors report no declaration of interest.